Search research articles
Contact Us
Filters
Showing results (141-150 of 229) with videos related to
Page
of 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2012
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
A Patrikidou, S Chabaud, I Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
British Journal of Cancer
|
October 24, 2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours
A Adenis, I Ray-Coquard, A Italiano, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 19, 2006
[Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]
C Le Péchoux, P Pautier, M Delannes, et al.
ESMO Open
|
September 13, 2025
Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing
H Vanacker, M Brahmi, D Pissaloux, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 18, 2019
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group
Marie Meurer, A Floquet, I Ray-Coquard, et al.
Oncoimmunology
|
May 4, 2016
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
E Verronèse, A Delgado, J Valladeau-Guilemond, et al.
British Journal of Cancer
|
July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
A Dufresne, F Bertucci, N Penel, et al.
Biosensors & Bioelectronics
|
July 17, 2012
Shewanella frigidimarina microbial fuel cells and the influence of divalent cations on current output
Lisa A Fitzgerald, Emily R Petersen, Dagmar H Leary, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
I Ray-Coquard, S Dussart, C Goillot, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 229) with videos related to
Sort By:
Page
of 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2012
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
A Patrikidou, S Chabaud, I Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
British Journal of Cancer
|
October 24, 2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours
A Adenis, I Ray-Coquard, A Italiano, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 19, 2006
[Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]
C Le Péchoux, P Pautier, M Delannes, et al.
ESMO Open
|
September 13, 2025
Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing
H Vanacker, M Brahmi, D Pissaloux, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 18, 2019
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group
Marie Meurer, A Floquet, I Ray-Coquard, et al.
Oncoimmunology
|
May 4, 2016
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
E Verronèse, A Delgado, J Valladeau-Guilemond, et al.
British Journal of Cancer
|
July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
A Dufresne, F Bertucci, N Penel, et al.
Biosensors & Bioelectronics
|
July 17, 2012
Shewanella frigidimarina microbial fuel cells and the influence of divalent cations on current output
Lisa A Fitzgerald, Emily R Petersen, Dagmar H Leary, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
I Ray-Coquard, S Dussart, C Goillot, et al.
Page
of 23